Cargando…

Association of malignant ascites with systemic inflammation and muscle loss after treatment in advanced‐stage ovarian cancer

BACKGROUND: Malignant ascites is prevalent in advanced‐stage ovarian cancer and may facilitate identification of the drivers of muscle loss. This study aimed to evaluate the association of ascites with changes in systemic inflammation and muscle after treatment of advanced‐stage ovarian cancer. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weng, Chia‐Sui, Huang, Wan‐Chun, Chang, Chih‐Long, Jan, Ya‐Ting, Chen, Tze‐Chien, Lee, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570096/ https://www.ncbi.nlm.nih.gov/pubmed/37503876 http://dx.doi.org/10.1002/jcsm.13289

Ejemplares similares

Explainable machine learning model for predicting skeletal muscle loss during surgery and adjuvant chemotherapy in ovarian cancer
por: Hsu, Wen‐Han, et al.
Publicado: (2023)

Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced‐stage ovarian cancer
por: Huang, Chueh‐Yi, et al.
Publicado: (2020)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment
por: Shi, Gang, et al.
Publicado: (2021)

The Proangiogenic Capabilities of Malignant Ascites Generated by Aggressive Ovarian Tumors
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2017)

Ascites Volumes and the Ovarian Cancer Microenvironment
por: Penet, Marie-France, et al.
Publicado: (2018)

Emerging treatment options for management of malignant ascites in patients with ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2012)

Malignant ascites: a source of therapeutic protein against ovarian cancer?
por: Ribaux, Pascale, et al.
Publicado: (2019)

Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification
por: Zeng, Wei-Juan, et al.
Publicado: (2015)

Progressive Skeletal Muscle Loss After Surgery and Adjuvant Radiotherapy Impact Survival Outcomes in Patients With Early Stage Cervical Cancer
por: Lee, Jie, et al.
Publicado: (2022)

Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma
por: Ho, Chih-Ming, et al.
Publicado: (2012)

Management of non-ovarian cancer malignant ascites through indwelling catheter drainage
por: Gu, Xiaoli, et al.
Publicado: (2016)

Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer
por: Kim, Soochi, et al.
Publicado: (2018)

Tumor cell-fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer
por: Han, Qing, et al.
Publicado: (2019)

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
por: den Ouden, Judith E., et al.
Publicado: (2020)

Malignant Ascites Promote Adhesion of Ovarian Cancer Cells to Peritoneal Mesothelium and Fibroblasts
por: Uruski, Paweł, et al.
Publicado: (2021)

Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
por: Chang, Chia-Hua, et al.
Publicado: (2020)

Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy
por: Hatzipetros, Ioannis, et al.
Publicado: (2013)

Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study
por: Chiang, An-Jen, et al.
Publicado: (2017)

Quality assessment of the guidelines for the management of malignant pleural effusions and ascites
por: Li, Jia-Xi, et al.
Publicado: (2020)

Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer
por: Yoshida-Court, Kyoko, et al.
Publicado: (2023)

Intestinal SIRT1 Deficiency-Related Intestinal Inflammation and Dysbiosis Aggravate TNFα-Mediated Renal Dysfunction in Cirrhotic Ascitic Mice
por: Chou, Yu-Te, et al.
Publicado: (2021)

Determination of the optimal volume of ascitic fluid for the precise diagnosis of malignant ascites
por: Zhang, Feifei, et al.
Publicado: (2019)

Chryseobacterium indologenes peritonitis in a patient with malignant ascites
por: Wang, Yung-Chih, et al.
Publicado: (2011)

Ascitic complement system in ovarian cancer
por: Bjørge, L, et al.
Publicado: (2005)

The bright side of ascites in ovarian cancer
por: Cohen, Marie, et al.
Publicado: (2014)

Ovarian cancer ascites induces skeletal muscle wasting in vitro and reflects sarcopenia in patients
por: Ubachs, Jorne, et al.
Publicado: (2021)

Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
por: Kondo, Tomohiro, et al.
Publicado: (2016)

The Epithelial-Mesenchymal Transition Initiated by Malignant Ascites Underlies the Transmesothelial Invasion of Ovarian Cancer Cells
por: Pakuła, Martyna, et al.
Publicado: (2019)

Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response
por: Rickard, Brittany P., et al.
Publicado: (2021)

Ovarian hyperstimulation syndrome and pregnancy luteoma mimicking malignant ascites: a rare case report
por: Chen, Jing, et al.
Publicado: (2023)

Malignant peritoneal mesothelioma with massive ascites as the first symptom: A case report
por: Huang, Xi, et al.
Publicado: (2022)

Management of ascites due to gastrointestinal malignancy
por: Saif, Muhammad W., et al.
Publicado: (2009)

Review of catumaxomab in the treatment of malignant ascites
por: Sebastian, Martin
Publicado: (2010)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Is It the Time for Laparoscopic Management of Early-stage Ovarian Malignancies?
por: Tantitamit, Tanitra, et al.
Publicado: (2018)

Meta-Analysis of VTE Risk: Ovarian Cancer Patients by Stage, Histology, Cytoreduction, and Ascites at Diagnosis
por: Weeks, Kristin S., et al.
Publicado: (2020)

Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer
por: Harding, V, et al.
Publicado: (2012)

Disaggregation and invasion of ovarian carcinoma ascites spheroids
por: Burleson, Kathryn M, et al.
Publicado: (2006)

Deciphering the ovarian cancer ascites fluid peptidome
por: Bery, Anand, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_blu3a5r75pt6eo3b9md5i5ke6d